Switch to
More onapp

Glenmark Life Sciences Ltd

GLS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹5,284 cr, stock is ranked 506
Low RiskStock is 1.49x as volatile as Nifty
433.355.15 (+1.20%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹5,284 cr, stock is ranked 506
Low RiskStock is 1.49x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
12.62
PB RatioPB Ratio
2.57
Dividend YieldDiv. Yield
4.87%
Sector PESector PE
35.90
Sector PBSector PB
4.36
Sector Div YldSctr Div Yld
0.88%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Glenmark Life Sciences Ltd is an India-based developer and manufacturer of active pharmaceutical ingredients (APIs). The Company’s product portfolio comprises of various therapeutic segments, which include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, gastrointestinal health, oncology, pain management and anti-infectives. The Company leverages its process research, analytical research and chemistry capabilities to provide contract development and manufacturing company (CDMO) services for a range of corporations and specialty companies. Its products include Adapalene, Alogliptin Benzoate, Amiodarone HCl, Esomeprazole Sodium, Eszopiclone, Etoricoxib, Omeprazole, Oxcarbazepine, Zolpidem Tartrate, Zonisamide and Voriconazole. Its products also include Vildagliptin, Aprepitant, Bosentan, Cilostazol, Deferasirox, Fluconazole, Ivacaftor, Pirfenidone, Riluzole, Sucralfate, Telmisartan and Umifenovir.

Investor PresentationView older 

Nov 17, 2022

PDF
View Older Presentations

Financial TrendFinancial statements 

20192020202120220.891.551.892.140.200.310.350.42
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Investor Presentation 
Announced OnNov 17, 2022

Glenmark Life Sciences Limited has informed the Exchange about Investor Presentation | Download

Glenmark Life Sciences Limited has informed the Exchange about Investor Presentation | Download

Investor Presentation 
Announced OnNov 17, 2022

Further to our communication dated November 11, 2022, attached is a copy of the presentation to be made at Glenmark Life Sciences Limited - Investor Day 2022 which is scheduled today at 15:45 IST in Mumbai.Kindly take the same on record and acknowledge receipt. | Download

Further to our communication dated November 11, 2022, attached is a copy of the presentation to be made at Glenmark Life Sciences Limited - Investor Day 2022 which is scheduled today at 15:45 IST in Mumbai.Kindly take the same on record and acknowledge receipt. | Download

Cash Dividend 
Ex. DateSep 15, 2022

Final • Div/Share: ₹ 10.5

See all events